Multiple myeloma in 2016: Fresh perspectives on treatment and moments of clarity
Data obtained in the past year underscored the benefit of a triplet regimen comprising bortezomib, lenalidomide, and dexamethasone for patients with newly-diagnosed multiple myeloma, and have provided high-level evidence supporting the safety of adding daratumumab to standard-of-care doublets for those with relapsed and/or refractory disease. As a result, achieving minimal residual disease-negativity at any stage of myeloma is now a realistic possibility.
Nat Rev Clin Oncol 2017; 14: 73–74. doi:10.1038/nrclinonc.2016.221